Pluristem Up Strong On Additional Compelling Results With PLX Cells

Israel-based Pluristem (NASDAQ:PSTI) announced that treatment with its Placental eXpanded (PLX) cells saved the life of a cancer patient with pancytopenia, a dangerous reduction in the number of red blood cells, white blood cells, and platelets caused by bone marrow failure. Pluristem noted that this is the second time in three months that bone marrow function was restored in a patient receiving PLX cells in the company’s compassionate use program. PSTI is trading up strongly pre-market as the news provides further validation of the company’s stem cell technology and its potential applications. Expect the shares to continue to rise throughout the trading session.